Drug Patents Expiring in 2027

1. List of Abilify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(3 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 15 November, 2002

Treatment: Adjunctive treatment of major depressive disorder (mdd)

Dosage: TABLET;ORAL

How can I launch a generic of ABILIFY before it's patent expiration?
More Information on Dosage

ABILIFY family patents

8

United States

3

China

3

Hong Kong

3

Japan

2

New Zealand

2

Georgia

2

Canada

2

Malaysia

2

Korea, Republic of

2

Argentina

2

Taiwan

2

Russia

2

European Union

1

Cyprus

1

Ecuador

1

Portugal

1

Brazil

1

Norway

1

Spain

1

Ukraine

1

Israel

1

Austria

1

Peru

1

Germany

1

Slovenia

1

Australia

1

Mexico

1

Poland

1

South Africa

1

Singapore

1

Denmark

2. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(3 years from now)

US9444503 OTSUKA Active signal processing personal health signal receivers
Nov, 2027

(4 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Adjunctive treatment of major depressive disorder (mdd); Method of using a receiver to identify a signal from a tablet embedded with a sensor that communicates information through the body of a patien...

Dosage: TABLET;ORAL

More Information on Dosage

ABILIFY MYCITE KIT family patents

15

United States

3

China

3

Hong Kong

3

Japan

3

European Union

2

New Zealand

2

Georgia

2

Canada

2

Malaysia

2

Korea, Republic of

2

Argentina

2

Taiwan

2

Russia

1

Cyprus

1

Ecuador

1

Portugal

1

Brazil

1

Norway

1

Spain

1

Ukraine

1

Israel

1

Austria

1

Peru

1

Germany

1

Slovenia

1

Australia

1

Mexico

1

Poland

1

South Africa

1

Singapore

1

Denmark

3. List of Abraxane drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8034375

(Pediatric)

BRISTOL MYERS SQUIBB CO Combinations and modes of administration of therapeutic agents and combination therapy
Feb, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
Pediatric Exclusivity (PED) Jun 6, 2023

Drugs and Companies using PACLITAXEL ingredient

Market Authorisation Date: 07 January, 2005

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of ABRAXANE before it's patent expiration?
More Information on Dosage

4. List of Actoplus Met drug patents

ACTOPLUS MET's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9101660 TAKEDA PHARMS USA Solid preparation
Jan, 2027

(3 years from now)

Drugs and Companies using METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 August, 2005

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ACTOPLUS MET family patents

4

Japan

2

New Zealand

2

Korea, Republic of

1

Cyprus

1

China

1

Portugal

1

Brazil

1

Canada

1

Norway

1

Spain

1

Hong Kong

1

Ukraine

1

Israel

1

United States

1

Costa Rica

1

Slovenia

1

Morocco

1

Australia

1

Mexico

1

South Africa

1

Poland

1

Russia

1

Colombia

1

Denmark

1

European Union

5. List of Acular Ls drug patents

ACULAR LS Litigations
Can you believe ACULAR LS received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8008338 ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
May, 2027

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8008338

(Pediatric)

ALLERGAN Ketorolac tromethamine compositions for treating or preventing ocular pain
Nov, 2027

(4 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: A method of treating or preventing ocular pain in a patient

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ACULAR LS before it's patent expiration?
More Information on Dosage

ACULAR LS family patents

16

United States

2

Canada

2

European Union

6. List of Adrenaclick drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7905352 IMPAX Kits containing medicine injection devices and containers
Apr, 2027

(3 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 30 May, 2003

Treatment: NA

Dosage: INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

ADRENACLICK family patents

17

United States

3

Canada

3

Norway

3

Taiwan

3

South Africa

3

Russia

3

China

3

European Union

2

Australia

2

Mexico

2

San Marino

2

Japan

2

Brazil

1

New Zealand

1

Hong Kong

7. List of Advil Allergy Sinus drug patents

ADVIL ALLERGY SINUS's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 GLAXOSMITHKLINE Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Feb, 2027

(3 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

ADVIL ALLERGY SINUS family patents

5

United States

3

Australia

3

China

2

New Zealand

2

Mexico

2

Peru

2

Taiwan

2

Hong Kong

2

Japan

2

Canada

2

European Union

1

Spain

1

South Africa

1

Colombia

1

Russia

1

Chile

1

Portugal

1

Argentina

8. List of Alsuma drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254 MERIDIAN MEDCL Autoinjector with needle depth adapter
Aug, 2027

(4 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 29 June, 2010

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

ALSUMA family patents

4

United States

1

Taiwan

1

Canada

1

European Union

9. List of Altabax drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(3 years from now)

Drugs and Companies using RETAPAMULIN ingredient

Market Authorisation Date: 12 April, 2007

Treatment: NA

Dosage: OINTMENT;TOPICAL

More Information on Dosage

ALTABAX family patents

4

United States

4

Japan

2

European Union

1

Austria

1

Spain

1

Germany

10. List of Amitiza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8779187 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(3 years from now)

US8338639 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Jan, 2027

(3 years from now)

US8026393 SUCAMPO PHARMA LLC Soft-gelatin capsule formulation
Oct, 2027

(4 years from now)

Drugs and Companies using LUBIPROSTONE ingredient

Market Authorisation Date: 31 January, 2006

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of AMITIZA before it's patent expiration?
More Information on Dosage

AMITIZA family patents

5

United States

3

China

2

Japan

1

New Zealand

1

Australia

1

Mexico

1

Israel

1

Canada

1

Spain

1

Russia

1

Korea, Republic of

1

Portugal

1

Denmark

1

Brazil

1

European Union

11. List of Amyvid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7687052 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(3 years from now)

US8506929 AVID RADIOPHARMS INC Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
Apr, 2027

(3 years from now)

Drugs and Companies using FLORBETAPIR F-18 ingredient

Market Authorisation Date: 06 April, 2012

Treatment: Amyvid is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

AMYVID family patents

5

United States

3

European Union

2

Cyprus

2

RS

2

Portugal

2

Norway

2

Spain

2

Croatia

2

Hungary

2

Slovenia

2

Poland

2

Denmark

1

New Zealand

1

Ecuador

1

China

1

Canada

1

Brazil

EA

1

EA

1

Korea, Republic of

1

Japan

1

Lithuania

1

Ukraine

1

Guatemala

1

Israel

1

Costa Rica

1

Austria

1

Australia

1

Mexico

1

South Africa

1

Taiwan

1

Singapore

1

Luxembourg

12. List of Anoro Ellipta drug patents

ANORO ELLIPTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M (M) Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.

Dosage: POWDER;INHALATION

More Information on Dosage

ANORO ELLIPTA family patents

25

United States

18

European Union

9

Japan

7

Spain

7

Australia

7

United Kingdom

6

Cyprus

6

China

6

Portugal

6

Canada

6

Hong Kong

6

Denmark

5

Brazil

5

Norway

5

Mexico

5

Poland

5

South Africa

4

Korea, Republic of

3

New Zealand

3

Israel

3

Hungary

3

Singapore

2

Croatia

EA

2

EA

2

Slovenia

1

Ecuador

1

Uruguay

1

Netherlands

1

Malaysia

1

Luxembourg

1

Lithuania

1

Ukraine

1

Peru

1

Argentina

1

Morocco

1

Taiwan

1

Colombia

AP

1

AP

13. List of Antizol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7553863 PAR PHARM INC Ultrapure 4-methylpyrazole
Jun, 2027

(4 years from now)

Drugs and Companies using FOMEPIZOLE ingredient

Market Authorisation Date: 04 December, 1997

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of ANTIZOL before it's patent expiration?
More Information on Dosage

ANTIZOL family patents

3

United States

1

Australia

1

Mexico

1

China

1

Korea, Republic of

1

Japan

1

Canada

1

European Union

14. List of Argatroban In Sodium Chloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7687516 EAGLE PHARMS Alcohol free formulation of argatroban
Sep, 2027

(4 years from now)

US7589106 EAGLE PHARMS Alcohol free formulation of argatroban
Sep, 2027

(4 years from now)

Drugs and Companies using ARGATROBAN ingredient

Market Authorisation Date: 29 June, 2011

Treatment: Method of treating an argatroban treatable condition; Method of treating thrombosis

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ARGATROBAN IN SODIUM CHLORIDE before it's patent expiration?
More Information on Dosage

ARGATROBAN IN SODIUM CHLORIDE family patents

9

United States

1

China

1

Japan

1

Canada

1

European Union

15. List of Arnuity Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M (M) Mar 1, 2026

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

ARNUITY ELLIPTA family patents

4

United States

4

United Kingdom

3

European Union

2

Cyprus

2

China

2

Portugal

2

Canada

2

Brazil

2

Spain

2

Hong Kong

2

Japan

2

Australia

2

Mexico

2

Poland

2

South Africa

2

Singapore

2

Denmark

1

New Zealand

1

Norway

1

Korea, Republic of

1

Israel

1

Hungary

16. List of Aubagio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Mar, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
M (M) Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

17. List of Auvi-q drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238108 KALEO INC Medicament delivery device having an electronic circuit system
Feb, 2027

(3 years from now)

US8206360 KALEO INC Devices, systems and methods for medicament delivery
Feb, 2027

(3 years from now)

US9724471 KALEO INC Devices, systems, and methods for medicament delivery
May, 2027

(3 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Market Authorisation Date: 10 August, 2012

Treatment: Method for confirming dose delivery

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

More Information on Dosage

AUVI-Q family patents

79

United States

15

Canada

14

United Kingdom

8

Japan

8

European Union

7

Australia

4

New Zealand

4

Mexico

4

China

3

Spain

3

Denmark

3

Israel

2

Poland

2

Hong Kong

18. List of Aveed drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7718640 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
Mar, 2027

(3 years from now)

US8338395 ENDO PHARMS INC Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
May, 2027

(3 years from now)

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 05 March, 2014

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypog...

Dosage: INJECTABLE;INTRAMUSCULAR

How can I launch a generic of AVEED before it's patent expiration?
More Information on Dosage

AVEED family patents

3

United States

2

China

2

ME

2

Korea, Republic of

2

South Africa

2

Russia

2

Denmark

2

European Union

1

New Zealand

1

Ecuador

1

Uruguay

1

Portugal

1

Brazil

1

Canada

1

Norway

1

Spain

1

Croatia

1

Jordan

EA

1

EA

1

Hong Kong

1

Japan

1

Saudi Arabia

1

Ukraine

1

Chile

YU

1

Yugoslavia

1

Israel

1

Costa Rica

1

Austria

1

Peru

1

Germany

1

Slovenia

1

Argentina

1

Australia

1

Iceland

1

Mexico

1

Poland

1

Taiwan

1

Colombia

IB

1

IB

19. List of Axiron drug patents

AXIRON's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9289586 ELI LILLY AND CO Spreading implement
Feb, 2027

(3 years from now)

US8807861 ELI LILLY AND CO Spreading implement
Feb, 2027

(3 years from now)

US8419307 ELI LILLY AND CO Spreading implement
Feb, 2027

(3 years from now)

US8435944 ELI LILLY AND CO Method and composition for transdermal drug delivery
Sep, 2027

(4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of transdermal administration of a physiologically active agent to a subject.; A method of increa...

Dosage: SOLUTION, METERED;TRANSDERMAL

How can I launch a generic of AXIRON before it's patent expiration?
More Information on Dosage

AXIRON family patents

11

United States

6

Australia

3

China

3

Korea, Republic of

3

Japan

2

Mexico

2

Canada

2

New Zealand

2

South Africa

EA

2

EA

2

Brazil

2

European Union

1

India

1

Spain

1

Hong Kong

20. List of Azilect drug patents

AZILECT's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7815942 TEVA Rasagiline formulations of improved content uniformity
Aug, 2027

(4 years from now)

Drugs and Companies using RASAGILINE MESYLATE ingredient

Market Authorisation Date: 16 May, 2006

Treatment: Treatment of parkinson's disease

Dosage: TABLET;ORAL

More Information on Dosage

AZILECT family patents

5

Korea, Republic of

4

United States

2

Japan

2

Canada

1

Australia

1

Mexico

1

New Zealand

1

Israel

1

Norway

1

Spain

1

South Africa

1

China

1

Russia

1

Hong Kong

1

Ukraine

1

Brazil

1

Iceland

1

European Union

21. List of Balcoltra drug patents

BALCOLTRA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7838042 AVION PHARMS Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions
Jun, 2027

(3 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; LEVONORGESTREL ingredient

Market Authorisation Date: 09 January, 2018

Treatment: Administration of ferrous bisglycinate tablets

Dosage: TABLET;ORAL

How can I launch a generic of BALCOLTRA before it's patent expiration?
More Information on Dosage

BALCOLTRA family patents

2

United States

1

Germany

1

European Union

22. List of Belbuca drug patents

Can you believe BELBUCA received compensation for the extended wait time during the regulatory approval process?
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 October, 2015

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Treatement of pain by transmucosal delivery ...

Dosage: FILM;BUCCAL

How can I launch a generic of BELBUCA before it's patent expiration?
More Information on Dosage

BELBUCA family patents

19

United States

3

Norway

3

Russia

3

European Union

2

New Zealand

2

China

2

Brazil

2

Hong Kong

2

Korea, Republic of

2

Japan

2

Israel

1

Cyprus

1

RS

1

Canada

1

Spain

1

Croatia

1

Ukraine

1

Hungary

1

Slovenia

1

Australia

1

Mexico

1

Poland

1

South Africa

1

Denmark

23. List of Beleodaq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835501 ACROTECH Pharmaceutical formulations of HDAC inhibitors
Oct, 2027

(4 years from now)

Drugs and Companies using BELINOSTAT ingredient

Market Authorisation Date: 03 July, 2014

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of BELEODAQ before it's patent expiration?
More Information on Dosage

BELEODAQ family patents

6

United States

2

China

2

Spain

EA

2

EA

2

Korea, Republic of

2

Japan

2

Israel

2

Denmark

2

European Union

1

New Zealand

1

Cyprus

1

Ecuador

1

RS

1

Portugal

1

Canada

1

Brazil

1

Norway

1

Croatia

1

Hong Kong

1

Ukraine

1

Austria

1

Slovenia

1

Australia

1

Mexico

1

United Kingdom

1

Poland

1

South Africa

24. List of Breo Ellipta drug patents

BREO ELLIPTA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8511304 GLAXO GRP LTD Medicament dispenser
Jun, 2027

(4 years from now)

US9333310 GLAXO GRP LTD Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXO GRP LTD Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: Indicated for the once-daily inhaled treatment for asthma in adults aged 18 years and older; Long-term, once daily maintenance treatment of airflow obstruction in pts with copd, including chronic bron...

Dosage: POWDER;INHALATION

More Information on Dosage

BREO ELLIPTA family patents

15

European Union

13

United States

7

Japan

7

United Kingdom

6

Australia

5

Spain

5

Hong Kong

4

Cyprus

4

China

4

Portugal

4

Canada

4

Brazil

4

Mexico

4

South Africa

4

Denmark

3

Poland

2

New Zealand

2

Norway

2

Korea, Republic of

2

Israel

2

Singapore

1

Hungary

1

Colombia

25. List of Bunavail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9655843 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

US8147866 BDSI Transmucosal delivery devices with enhanced uptake
Jul, 2027

(4 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Treatment of opioid dependence; Maintenance treatment of opioid dependence

Dosage: FILM;BUCCAL

How can I launch a generic of BUNAVAIL before it's patent expiration?
More Information on Dosage

BUNAVAIL family patents

19

United States

3

Norway

3

Russia

3

European Union

2

New Zealand

2

China

2

Brazil

2

Hong Kong

2

Korea, Republic of

2

Japan

2

Israel

1

Cyprus

1

RS

1

Canada

1

Spain

1

Croatia

1

Ukraine

1

Hungary

1

Slovenia

1

Australia

1

Mexico

1

Poland

1

South Africa

1

Denmark

26. List of Bydureon drug patents

BYDUREON's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(3 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(3 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(3 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element
Nov, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON family patents

7

Japan

7

United States

EA

5

EA

5

European Union

4

New Zealand

4

Israel

4

Taiwan

3

China

3

Brazil

3

Canada

3

Spain

3

Mexico

2

Peru

2

Poland

2

Singapore

2

Denmark

1

Cyprus

1

RS

1

Switzerland

1

Portugal

1

Norway

1

Malaysia

1

Croatia

1

Hong Kong

1

Korea, Republic of

1

Chile

1

Ukraine

1

Austria

1

Germany

1

Slovenia

1

Argentina

1

Australia

1

Philippines

1

South Africa

1

Colombia

27. List of Bydureon Bcise drug patents

BYDUREON BCISE's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(3 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(3 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(3 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

BYDUREON BCISE family patents

6

Japan

EA

5

EA

5

United States

4

New Zealand

4

Israel

4

Taiwan

4

European Union

3

Canada

3

Brazil

3

Spain

3

Mexico

2

China

2

Peru

2

Singapore

1

Cyprus

1

RS

1

Portugal

1

Norway

1

Malaysia

1

Croatia

1

Hong Kong

1

Korea, Republic of

1

Chile

1

Ukraine

1

Slovenia

1

Argentina

1

Australia

1

Philippines

1

South Africa

1

Poland

1

Colombia

1

Denmark

28. List of Byfavo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9914738 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US10472365 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US10961250 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

US9777007 ACACIA Short-acting benzodiazepine salts and their polymorphic forms
Jul, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 6, 2025

Drugs and Companies using REMIMAZOLAM BESYLATE ingredient

NCE-1 date: 2024-10-06

Market Authorisation Date: 06 October, 2020

Treatment: Use of remimazolam for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BYFAVO family patents

7

United States

4

China

4

Hong Kong

3

Korea, Republic of

3

United Kingdom

2

Japan

1

Portugal

1

Canada

1

Brazil

1

Spain

1

Austria

1

Germany

1

Slovenia

1

Australia

1

Mexico

1

Poland

1

Russia

1

Denmark

1

European Union

29. List of Byvalson drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7838552 ALLERGAN Compositions comprising nebivolol
Oct, 2027

(4 years from now)

Drugs and Companies using NEBIVOLOL HYDROCHLORIDE; VALSARTAN ingredient

Market Authorisation Date: 03 June, 2016

Treatment: Method of treating hypertension

Dosage: TABLET;ORAL

How can I launch a generic of BYVALSON before it's patent expiration?
More Information on Dosage

BYVALSON family patents

8

United States

5

European Union

3

China

3

Russia

2

New Zealand

2

Australia

AP

2

AP

2

South Africa

2

Singapore

2

Korea, Republic of

2

Canada

2

Israel

1

Austria

1

Hong Kong

1

Japan

30. List of Cabenuva Kit drug patents

CABENUVA KIT's oppositions filed in EPO
CABENUVA KIT Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11389447 VIIV HLTHCARE Aqueous suspensions of TMC278
Jun, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 21, 2026
New Patient Population (NPP) Mar 29, 2025
New Dosing Schedule (D) Jan 31, 2025

Drugs and Companies using CABOTEGRAVIR; RILPIVIRINE ingredient

NCE-1 date: 2025-01-21

Market Authorisation Date: 21 January, 2021

Treatment: Treatment of hiv-1 infection in adults and adolescents 12 years of age and older and weighing at least 35 kg by monthly administration of rilpivirine suspension as part of combination therapy

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

CABENUVA KIT family patents

5

United States

4

European Union

1

New Zealand

1

Cyprus

1

RS

1

Uruguay

1

China

1

Portugal

1

Canada

1

Brazil

1

Spain

1

Croatia

1

Jordan

EA

1

EA

1

Chile

1

Korea, Republic of

1

Japan

1

Lithuania

1

Ukraine

1

Israel

1

Hungary

1

Peru

1

Slovenia

1

Argentina

1

Australia

1

Mexico

1

Taiwan

1

Poland

1

Singapore

AP

1

AP

1

Denmark

31. List of Camcevi Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9572857 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

US9744207 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

US10646572 ACCORD Pharmaceutical compositions with enhanced stability
Jan, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 25, 2024

Drugs and Companies using LEUPROLIDE MESYLATE ingredient

Market Authorisation Date: 25 May, 2021

Treatment: NA

Dosage: EMULSION;SUBCUTANEOUS

More Information on Dosage

CAMCEVI KIT family patents

7

United States

2

Korea, Republic of

1

Australia

1

Mexico

1

Spain

1

Taiwan

1

China

1

Russia

1

Hong Kong

1

Slovenia

1

Japan

1

Canada

1

Brazil

1

Denmark

1

European Union

32. List of Cardene drug patents

CARDENE Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758616 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US11547758 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7659291 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US8455524 CHIESI Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions
Apr, 2027

(3 years from now)

US7612102 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

US9364564 CHIESI Pre-mixed, ready-to-use pharmaceutical compositions
Dec, 2027

(4 years from now)

Drugs and Companies using NICARDIPINE HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 1992

Treatment: Method for treating acute elevations of blood pressure in human subject in need thereof

Dosage: INJECTABLE;INJECTION; INJECTABLE;INTRAVENOUS

How can I launch a generic of CARDENE before it's patent expiration?
More Information on Dosage

CARDENE family patents

16

United States

3

Canada

2

New Zealand

2

Mexico

2

Australia

2

China

2

Korea, Republic of

2

Japan

2

Brazil

2

European Union

33. List of Chloraprep One-step drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7422388 BECTON DICKINSON CO Applicator for coloring antiseptic
Apr, 2027

(3 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL ingredient

Market Authorisation Date: 14 July, 2000

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SPONGE;TOPICAL

More Information on Dosage

CHLORAPREP ONE-STEP family patents

6

United States

2

European Union

1

Australia

1

Mexico

1

Spain

1

Japan

1

Canada

1

Brazil

34. List of Chlorhexidine Gluconate drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7935093 SAGE PRODS Disinfectant delivery system and method of providing alcohol-free disinfection
Oct, 2027

(4 years from now)

Drugs and Companies using CHLORHEXIDINE GLUCONATE ingredient

Market Authorisation Date: 25 April, 2005

Treatment: For the preparation of skin prior to surgery; Helps reduce bacteria that can potentially cause skin infection

Dosage: CLOTH;TOPICAL

More Information on Dosage

CHLORHEXIDINE GLUCONATE family patents

7

United States

2

Canada

35. List of Colazal drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7625884

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(3 years from now)

US7452872

(Pediatric)

VALEANT PHARMS INTL Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
Feb, 2027

(3 years from now)

Drugs and Companies using BALSALAZIDE DISODIUM ingredient

Market Authorisation Date: 18 July, 2000

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of COLAZAL before it's patent expiration?
More Information on Dosage

36. List of Combivent Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9027967 BOEHRINGER INGELHEIM Device for clamping a fluidic component
Mar, 2027

(3 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

COMBIVENT RESPIMAT family patents

2

United States

2

Germany

2

European Union

1

Cyprus

1

Ecuador

1

Egypt

1

RS

1

China

1

Portugal

1

Brazil

1

Canada

1

Norway

1

Spain

1

Croatia

EA

1

EA

1

ME

1

Korea, Republic of

1

Japan

1

Ukraine

1

Austria

1

Slovenia

1

Australia

1

Mexico

1

Poland

1

South Africa

1

Colombia

1

Denmark

37. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9107837 NALPROPION Sustained release formulation of naltrexone
Jun, 2027

(3 years from now)

US8318788 NALPROPION Layered pharmaceutical formulations
Nov, 2027

(4 years from now)

US9125868 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US8722085 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

US10307376 NALPROPION Methods for administering weight loss medications
Nov, 2027

(4 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity; Use of naltrexone and bupropion in a layered formulation for chronic weight m...

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

CONTRAVE family patents

25

United States

11

Korea, Republic of

9

Japan

5

Taiwan

4

European Union

3

Mexico

3

Argentina

2

Australia

2

Spain

2

China

2

Russia

2

Chile

2

Canada

1

Israel

1

Austria

1

Germany

1

Hong Kong

1

Denmark

38. List of Corlanor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7867996

(Pediatric)

AMGEN INC γ-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
Jun, 2027

(4 years from now)

Drugs and Companies using IVABRADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 April, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of CORLANOR before it's patent expiration?
More Information on Dosage

39. List of Cotellic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8362002

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
Apr, 2027

(3 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 28, 2025
M (M) Jul 28, 2025
Orphan Drug Exclusivity (ODE) Oct 28, 2029
Pediatric Exclusivity (PED) Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

40. List of Cresemba drug patents

CRESEMBA's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603280 ASTELLAS Active ingredient containing stabilised solid medicinal forms and methods for the production thereof
Sep, 2027

(4 years from now)

US10206879 ASTELLAS Active ingredient containing stabilised solid forms and method for the production thereof
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 6, 2020
ODE* (ODE*) Mar 6, 2022
Orphan Drug Exclusivity (ODE) Mar 6, 2022
Generating Antibiotic Incentives Now (GAIN) Mar 6, 2027

Drugs and Companies using ISAVUCONAZONIUM SULFATE ingredient

NCE-1 date: 2026-03-06

Market Authorisation Date: 06 March, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

CRESEMBA family patents

6

United States

3

European Union

1

Australia

1

Austria

1

Germany

1

Denmark

1

Canada

41. List of Daklinza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9421192 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

US8642025 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8900566 BRISTOL-MYERS SQUIBB Hepatitis C virus inhibitors
Aug, 2027

(4 years from now)

Drugs and Companies using DACLATASVIR DIHYDROCHLORIDE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Method of inhibiting hepatitis c virus with daklinza and at least one additional compound having anti-hcv activity; Method of inhibiting hepatitis c virus

Dosage: TABLET;ORAL

More Information on Dosage

DAKLINZA family patents

15

United States

5

European Union

3

Cyprus

3

Spain